Patent ID: 7723023
Filing Date: 2010-05-25
Classification: B01J,C12Q

Abstract:
1. A method of evaluating and/or predicting whether a candidate compound has a beneficial therapeutic receptor active drug activity or a hallucinogenic or toxic side-effect as compared to a group of reference compounds that have known beneficial therapeutic receptor active drug activities or known hallucinogenic or toxic side-effects comprising: a) contacting a candidate compound and a group of reference compounds with a cell in vitro or in vivo for a time period to allow transcription of one or more Intrinsic Reporters of Cell Signaling (IRCS) comprising one or more first/early response genes in the cell, wherein the time period is determined to represent the early accumulation of one or more RNA transcripts, and wherein the time period extends from the time of contact of the candidate compound with the cell to the time of transcription of the first/early genes in a signal transduction pathway and up to 2 hours after said contact; and wherein the candidate compound and reference compounds are tested during the same time period; b) determining the response profile for the one or more IRCS; and c) comparing the response profile for the one or more IRCS determined in step b) with a corresponding response profile for a group of reference compounds having known beneficial therapeutic receptor active drug activities or known hallucinogenic or toxic side effects; wherein the IRCS demonstrate a reproducible and statistically significant increase of 1.3 fold or greater of the RNA level transcribed from an early response gene by one hour after exposure to a candidate compound at 37° C.; wherein said comparing of the response profile for the one or more IRCS to the response profile to each of the known reference compounds within the group determines if the response profile is similar to that of a reference compound having known beneficial therapeutic receptor active drug activity, wherein the candidate compound is selected for beneficial therapeutic receptor active drug activity; or determines if the response profile is similar to that of a reference compound having known hallucinogenic or toxic side effects, wherein the candidate compound is rejected for having hallucinogenic or toxic side effects and said comparing is performed using statistical analyses.